Egyesült Államok - angol - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - promethazine hydrochloride 6.25 mg in 5 ml - promethazine with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. the combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal respiratory depression in this age population. codeine sulfate is contraindicated for post-operative pain management in children who have undergone tonsillectomy and/or adenoidectomy. (see warnings - death related to ultra- rapid metabolism of codeine to morphine ). codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine hydrochloride is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. prometha

Egyesült Államok - angol - NLM (National Library of Medicine)

henry schein animal health - propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - propylene glycol 1034.2 g in 1 l - for use as an aid in prevention and treatment of ketosis (acetonemia) in dairy cattle.

Egyesült Államok - angol - NLM (National Library of Medicine)

first priority incorporated - propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - propylene glycol 1034.2 g in 1 l - for use as an aid in prevention and treatment of ketosis (acetonemia) in dairy cattle.

Egyesült Államok - angol - NLM (National Library of Medicine)

durvet, inc. - propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - propylene glycol 1034.2 g in 1 l - for use as an aid in prevention and treatment of ketosis for use as an aid in prevention and treatment of ketosis (acetonemia) in dairy cattle. livestock drug

Egyesült Államok - angol - NLM (National Library of Medicine)

lannett company, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 100 mg in 5 ml - oxycodone hydrochloride oral solution (5 mg per ml) , an opioid agonist, is indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. oxycodone hydrochloride oral solution 100 mg per 5 ml (20 mg per ml) , an opioid agonist, is indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. oxycodone hydrochloride oral solution usp, 100 mg per 5 ml (20 mg per ml) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. oxycodone hydrochloride is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. oxycodone hydrochloride is contraindicated in any patient who has or is sus

Egyesült Államok - angol - NLM (National Library of Medicine)

rebel distributors corp - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - nefazodone hydrochloride 200 mg - nefazodone hydrochloride tablets are indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6 week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of in

Egyesült Államok - angol - NLM (National Library of Medicine)

stat rx usa llc - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - nefazodone hydrochloride 100 mg - nefazodone hydrochloride tablets are indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6 week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of in

Egyesült Államok - angol - NLM (National Library of Medicine)

physicians total care, inc. - paroxetine hydrochloride (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 12.5 mg - paroxetine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine hydrochloride extended-release tablets in the treatment of a major depressive episode was established in two 12 week controlled trials of outpatients whose diagnoses corresponded to the dsm-iv category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning and includes the presence of at least 5 of the following 9 symptoms during the same 2 week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impai

Egyesült Államok - angol - NLM (National Library of Medicine)

mwi/vet one - propylene glycol (unii: 6dc9q167v3) (propylene glycol - unii:6dc9q167v3) - propylene glycol 1034.2 g in 1 l - oral ketosis treatment for dairy cattle for use in the treatment and prevention of bovine ketosis (acetonemia).

Egyesült Államok - angol - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm). the efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with mdd. the efficacy of the sustained-release formulation of bupropion in the maintenance treatment of mdd was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see clinical studies (14.1)]. bupropion hydrochloride extended-release tablets (xl) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (sad). the efficacy of bupropion hydrochloride extended-release tablets (xl) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials i